Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease
Emily Conley, CEO of Berkeley, CA-based Renasant …
The Long Run with Luke Timmerman · Timmerman Report
December 15, 20251h 7m
Audio is streamed directly from the publisher (feeds.soundcloud.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).